| 生物活性 | |||
|---|---|---|---|
| 靶点 | 
 | ||
| 描述 | AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM[1].[2].[3]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 | 
| NCT03160326 | - | Recruiting | March 2020 | United States, California ... 展开 >> San Francisco VA Medical Center Recruiting San Francisco, California, United States, 94121 Contact: Julie Doyle 415-221-4810 ext 2597 Julie.Doyle2@va.gov Principal Investigator: Cynthia Delgado, MD United States, District of Columbia Washington DC VA Medical Center Recruiting Washington, District of Columbia, United States, 20422 Contact: Brian M Hoover, MS 202-745-8000 ext 55826 Brian.Hoover@va.gov Principal Investigator: Michael Harris-Love, DSc Sub-Investigator: Haniel Hernandez, DPT Sub-Investigator: Sholey Argani, MD Sub-Investigator: Marc Blackman, MD 收起 << | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
| 1 mM 5 mM 10 mM | 1.80mL 0.36mL 0.18mL | 9.01mL 1.80mL 0.90mL | 18.01mL 3.60mL 1.80mL | 
| 参考文献 | 
|---|